Tuesday, January 29, 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases. more..

4 comments:

  1. Wow, this is really impressive stuff! I just personally wanted to thank you sharing this information, since I do write for a clinical research blog based in Florida. I really can't wait to hear what the results are from the final phases of testing, but this would still make a great article for Lupus Awareness Month 2013.

    ReplyDelete
  2. I have to agree wholeheartedly with the statement made by Avail Clinical News. This information shows that there are certainly a lot of promising breakthroughs coming from research on lupus. I just hope they continue to get the funding they need.

    ReplyDelete
  3. Thanks for sharing this information Kendra! I hope that more people get a chance to read about this over May. I would certainly like to know what is in the works for the next phase of clinical testing on this particular drug.

    ReplyDelete
  4. I am an Immupharma shareholder and came across your blog whilst researching the company. Just to let you know that progress has been made in the sense that Immupharma have now secured a £50 million loan facility which will allow them to take Lupuzor into phase III trials. We are awaiting the appointment of a CRO (Contract Research Organisation) who will carry out the trials. Hopefully Lupuzor is now one step closer to coming to market.

    ReplyDelete